Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Wehr, Claudia ^a   Müller, Fabian ^b   Schüler, Julia ^c   Tomann, Tina ^b   Nitschke, Claudia ^a   Seismann, Henning ^b   Spillner, Edzard ^d   Klingner, Kerstin ^c   Schneider Merck, Tanja ^b   Binder, Mascha ^b   Fiebig, Heinz Herbert ^c   Mertelsmann, Roland ^a   Trepel, Martin ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CHARLES RIVER LABORATORIES   (United States)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

B cell receptor; Burkitt's lymphoma; epitope mimic; phage display; xenograft model

Indexed keywords

ALANYLLYSYLTYROSYLASPARAGINYLSERYLPROLYLTRYPTOPHYLLEUCYLTHREONINYLPROLYLLEUCYLLEUCINE; ANTINEOPLASTIC AGENT; ARGINYLTRYPTOPHYLTYROSYLGLUTAMYLARGINYLGLYCYLLYSYLGLUTAMINYLPROLYLPROLYLLEUCYLSERYLLEUCYLGLYCYLTRYPTOPHYLVALYLSERYLSERINE; B LYMPHOCYTE RECEPTOR; CALCIUM; SERYLALANYLLEUCYLANALYLCYSTEINYLPROLYLSERYLPROLYLTYROSYLCYSTEINYLARGINYLSERYLSERYLPROLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BURKITT LYMPHOMA; CALCIUM TRANSPORT; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOCYTOSIS; EXPERIMENTAL MOUSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN TARGETING; RECEPTOR BINDING; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BURKITT LYMPHOMA; CALCIUM; CELL LINE, TUMOR; ENDOCYTOSIS; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR MIMICRY; MOLECULAR TARGETED THERAPY; PEPTIDES; RECEPTORS, ANTIGEN, B-CELL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861611470     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26464     Document Type: Article

References (50)

1. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M,. The epitope recognized by rituximab. Blood 2006; 108: 1975-8.
2. Wu AM, Senter PD,. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-46.
3. Arnold A, Cossman J, Bakhshi A, Jaffe ES, Waldmann TA, Korsmeyer SJ,. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med 1983; 309: 1593-9.
4. Levy R, Warnke R, Dorfman RF, Haimovich J,. The monoclonality of human B-cell lymphomas. J Exp Med 1977; 145: 1014-28.
5. Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, Robb RJ, Popescu MC, Kwak LW,. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 2007; 109: 5160-3.
6. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R,. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209-15.
7. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R,. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998; 92: 1184-90.
8. Renschler MF, Bhatt RR, Dower WJ, Levy R,. Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc Natl Acad Sci USA 1994; 91: 3623-7.
9. Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, et al. In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder. Blood 2010; 116: 226-38.
10. Carroll WL, Link MP, Cleary ML, Bologna S, Carswell C, Amylon MD, Smith SD, Levy R,. Idiotype as a tumor-specific marker in childhood B cell acute lymphoblastic leukemia. Blood 1988; 71: 1068-73.
11. Braren I, Greunke K, Umland O, Deckers S, Bredehorst R, Spillner E,. Comparative expression of different antibody formats in mammalian cells and Pichia pastoris. Biotechnol Appl Biochem 2007; 47: 205-14.
12. Scott JK, Smith GP,. Searching for peptide ligands with an epitope library. Science 1990; 249: 386-90.
13. Jäger S, Jahnke A, Wilmes T, Adebahr S, Vogtle FN, Delima-Hahn E, Pfeifer D, Berg T, Lubbert M, Trepel M,. Leukemia-targeting ligands isolated from phage-display peptide libraries. Leukemia 2007; 21: 411-20.
14. Binder M, Vögtle FN, Michelfelder S, Müller F, Illerhaus G, Sundararajan S, Mertelsmann R, Trepel M,. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 2007; 67: 3518-23.
15. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W,. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001; 7: 1249-53.
16. Renschler MF, Wada HG, Fok KS, Levy R,. B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. Cancer Res 1995; 55: 5642-7.
17. Carey GB, Donjerkovic D, Mueller CM, Liu S, Hinshaw JA, Tonnetti L, Davidson W, Scott DW,. B-cell receptor and Fas-mediated signals for life and death. Immunol Rev 2000; 176: 105-15.
18. Eldering E, VanLier RA,. B-cell antigen receptor-induced apoptosis: looking for clues. Immunol Lett 2005; 96: 187-94.
19. Mongini PK, Liu Q, Vilensky MA, Highet PF, Inman JK,. Evidence for an upper affinity threshold for anti-IgM-induced apoptosis in a human B-cell lymphoma. Blood 1998; 92: 3756-71.
20. Jares P, Colomer D, Campo E,. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750-62.
21. Smit LA, van Maldegem F, Langerak AW, van der Schoot CE, de Wit MJ, Bea S, Campo E, Bende RJ, van Noesel CJ,. Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation. Haematologica 2006; 91: 903-11.
22. Bellan C, Lazzi S, Hummel M, Palummo N, de Santi M, Amato T, Nyagol J, Sabattini E, Lazure T, Pileri SA, Raphael M, Stein H, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106: 1031-6.
23. Thelander EF, Rosenquist R,. Molecular genetic characterization reveals new subsets of mantle cell lymphoma. Leuk Lymphoma 2008: 1-8.
24. Thorselius M, Walsh S, Eriksson I, Thunberg U, Johnson A, Backlin C, Enblad G, Sundstrom C, Roos G, Rosenquist R,. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol 2002; 68: 217-24.
25. Stevenson FK, Caligaris-Cappio F,. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103: 4389-95.
26. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, Cuoghi A, Torelli G,. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001; 159: 253-61.
27. Adam P, Haralambieva E, Hartmann M, Mao Z, Ott G, Rosenwald A,. Rare occurrence of IgVH gene translocations and restricted IgVH gene repertoire in ocular MALT-type lymphoma. Haematologica 2008; 93: 319-20.
28. Traverse-Glehen A, Davi F, Ben Simon E, Callet-Bauchu E, Felman P, Baseggio L, Gazzo S, Thieblemont C, Charlot C, Coiffier B, Berger F, Salles G,. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica 2005; 90: 470-8.
29. Montesinos-Rongen M, Kuppers R, Schluter D, Spieker T, Van Roost D, Schaller C, Reifenberger G, Wiestler OD, Deckert-Schluter M,. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999; 155: 2077-86.
30. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, Laoutaris N, Karlsson K, Baran-Marzsak F, Tsaftaris A, Moreno C, Anagnostopoulos A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111: 1524-33.
31. Binder M, Muller F, Jackst A, Lechenne B, Pantic M, Bacher U, Eulenburg CZ, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M,. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011; 117: 1891-900.
32. Binder M, Lechenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, Schluter H, Braren I, Spillner E, Trepel M,. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS One 2010; 5: e15992.
33. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM,. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 2008; 6: e152.
34. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA,. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111: 2230-7.
35. Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC, Potter TA, Refaeli Y,. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009; 113: 2508-16.
36. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, Efremov DG,. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010; 116: 4894-905.
37. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-85.
38. Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H,. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res 2006; 66: 4496-502.
39. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, Kwak LW,. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 2009; 114: 4142-9.
40. Eeva J, Pelkonen J,. Mechanisms of B cell receptor induced apoptosis. Apoptosis 2004; 9: 525-31.
41. Vuist WM, Levy R, Maloney DG,. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 1994; 83: 899-906.
42. George AJ, Spellerberg MB, Stevenson FK,. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics. J Immunol 1988; 140: 1695-701.
43. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R,. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 1985; 312: 1658-65.
44. Shadidi M, Sioud M,. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J 2003; 17: 256-8.
45. Arap W, Pasqualini R, Ruoslahti E,. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80.
46. De Angelis F, Pujia A, Falcone C, Iaccino E, Palmieri C, Liberale C, Mecarini F, Candeloro P, Luberto L, de Laurentiis A, Das G, Scala G, et al. Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context. Nanoscale 2010; 2: 2230-6.
47. Ricart AD, Tolcher AW,. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 2007; 4: 245-55.
48. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ,. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58: 221-37.
49. Niiro H, Clark EA,. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002; 2: 945-56.
50. Udhayakumar V, Kumar L, Subbarao B,. The influence of avidity on signaling murine B lymphocytes with monoclonal anti-IgM antibodies. Effects of B cell proliferation versus growth inhibition (tolerance) of an immature B cell lymphoma. J Immunol 1991; 146: 4120-9.